Catalyst Wire Dossier Catalyst Wire Dossier

IMGN901

lorvotuzumab mertansine · ImmunoGen, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for IMGN901, covering 2014-11-21 to 2018-01-18. Get the full timeline:

Most recent: Clinical Trial Update: A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer [Phase 1, Phase 2]

See pricing